drugset / Trial / NCT00738062
Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to assess the durability of effect of Droxidopa in treating symptoms of neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure Autonomic Failure, Multiple System Atrophy, Parkinson's Disease), Non-diabetic neuropathy, or Beta Hydroxylase deficiency.
Timeline
- Start
- 2008-01
- Primary completion
- 2010-12
- Completion
- 2010-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Droxidopa | Small molecule | 100 mg | Oral |
| Comparator | Droxidopa | Small molecule | 200 mg | Oral |
| Comparator | Droxidopa | Small molecule | 300 mg | Oral |
| Comparator | Droxidopa | Small molecule | 400 mg | Oral |
| Comparator | Droxidopa | Small molecule | 500 mg | Oral |
| Comparator | Droxidopa | Small molecule | 600 mg | Oral |